Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer

Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer

(2016) T. Kinoshita et al.   ANNALS OF ONCOLOGY

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

(2016) Xuefei Li et al.   BMC CANCER

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

(2016) Takaaki Tokito et al.   EUROPEAN JOURNAL OF CANCER

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient

(2016) Lixia Ju et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

(2015) Kurt A. Schalper et al.   JNCI-Journal of the National Cancer Institute

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

(2015) Antonio Calles et al.   Journal of Thoracic Oncology

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

(2015) Moon-Young Kim et al.   LUNG CANCER

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma

(2015) Wendy A. Cooper et al.   LUNG CANCER

Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

(2015) Jaemoon Koh et al.   MODERN PATHOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer

(2015) Ningning Cheng et al.   Oncotarget

B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer

(2015) Yixiang Mao et al.   Oncotarget

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

(2015) Yanna Tang et al.   Oncotarget

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

(2015) Kurt A. Schalper et al.   JNCI-Journal of the National Cancer Institute

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

(2015) Lars Henning Schmidt et al.   PLoS One

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

(2014) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

(2014) Yang Zhang et al.   OncoTargets and Therapy

KIF5B-RETfusions in Chinese patients with non-small cell lung cancer

(2013) Weijing Cai et al.   CANCER

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Association ofEGFRmutation orALKrearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma

(2012) Shengxiang Ren et al.   CANCER

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms

(2009) Enrico Ruffini et al.   ANNALS OF THORACIC SURGERY